| CSN83915 |
α-Methyl-DL-aspartic acid
|
2792-66-7 |
α-methyl-dl-aspartic acid is an inhibitor of argininosuccinate synthase. |
| CSN35813 |
Propionylcarnitine
|
17298-37-2 |
Propionylcarnitine chloride is a homolog of acetylcarnitine chloride and an important intermediate in lipid metabolism. |
| CSN155318 |
(S)-2-Aminohexanedioic acid
|
1118-90-7 |
L-α aminoadipic acid (L-AAA), a glutamate analogue, is a specific astrocyte toxin. |
| CSN147957 |
S-(2-(3-((2R)-4-(((((((2R,3S,4R,5R)-5-(6-Amino-9H-purin-9-yl)-4-hydroxy-3-(phosphonooxy)tetrahydrofuran-2-yl)methoxy)(hydroxy)phosphoryl)oxy)(hydroxy)phosphoryl)oxy)-2-hydroxy-3,3-dimethylbutanamido)propanamido)ethyl) benzothioate
|
6756-74-7 |
Benzoyl CoA is an intermediate molecule in the pathway of the aerobic benzoate oxidation for Azoarcus evansii and for Bacillus Stearothermophilus-like strain. |
| CSN_mab1015 |
Camrelizumab
|
1798286-48-2 |
|
| CSN_mab1022 |
Belimumab
|
356547-88-1 |
|
| CSN_mab1026 |
Brodalumab (anti-IL17RA)
|
1174395-19-7 |
|
| CSN_mab1035 |
Necitumumab
|
906805-06-9 |
|
| CSN_mab1041 |
Toripalimab
|
1924598-82-2 |
|
| CSN_mab1039 |
Sintilimab
|
2072873-06-2 |
|
| CSN_mab1040 |
Tislelizumab
|
1858168-59-8 |
|
| CSN73031 |
Amatuximab
|
931402-35-6 |
|
| CSN73033 |
Etokimab
|
2022981-44-6 |
|
| CSN73298 |
Bemarituzumab
|
1952272-74-0 |
|
| CSN73301 |
Aprutumab
|
1634620-63-5 |
|
| CSN73268 |
Lemzoparlimab
|
2377483-71-9 |
|
| CSN79768 |
Enfortumab
|
1448664-46-7 |
|
| CSN80313 |
Cusatuzumab
|
1864871-20-4 |
|
| CSN79980 |
Margetuximab
|
1350624-75-7 |
|
| CSN80043 |
Batoclimab
|
2187430-05-1 |
|
| CSN81531 |
Tinurilimab
|
2226224-30-0 |
|
| CSN89707 |
Zagotenemab
|
2019133-28-7 |
|
| CSN90055 |
Clazakizumab
|
1236278-28-6 |
|
| CSN90027 |
Palivizumab
|
188039-54-5 |
|
| CSN90068 |
Mavrilimumab
|
1085337-57-0 |
|
| CSN90053 |
Tralokinumab
|
1044515-88-9 |
|
| CSN90116 |
Tafasitamab
|
1422527-84-1 |
|
| CSN90048 |
Nipocalimab
|
2211985-36-1 |
|
| CSN89896 |
Polatuzumab
|
2279068-37-8 |
|
| CSN90069 |
Simtuzumab
|
1318075-13-6 |
|
| CSN90049 |
Urelumab
|
934823-49-1 |
|
| CSN89845 |
Utomilumab
|
1417318-27-4 |
|
| CSN90221 |
Teprotumumab
|
1036734-93-6 |
|
| CSN90244 |
Trypsin
|
9002-07-7 |
|
| CSN91651 |
Tilvestamab
|
2226775-26-2 |
|
| CSN91709 |
Labetuzumab
|
219649-07-7 |
|
| CSN91660 |
Lucatumumab
|
903512-50-5 |
|
| CSN91657 |
Tilavonemab
|
2096513-89-0 |
|
| CSN91658 |
Nemolizumab
|
1476039-58-3 |
|
| CSN91696 |
Gevokizumab
|
1129435-60-4 |
|
| CSN91668 |
Ivuxolimab
|
2128729-41-7 |
|
| CSN91708 |
Enibarcimab
|
2305638-98-4 |
|
| CSN91665 |
Vudalimab
|
2329669-72-7 |
|
| CSN91681 |
Anifrolumab
|
1326232-46-5 |
|
| CSN91666 |
Uliledlimab
|
2378407-27-1 |
|
| CSN52384 |
Anti-HEL-Human IgG1(L234A/L235A/G237A)-kappa Isotype control
|
N/A |
|
